Abstract
The objective of this study is to determine if a non-immunogenic Dunning's rat prostate cancer cell line, MATLyLu, can become immunogenic by reducing the endogenous production of TGF-β1. An expression construct containing a DNA sequence in an antisense orientation to TGF-β1 (TGF-β1 antisense) was stably transfected into MATLyLu cells. Following transfection, cellular content of TGF-β1 reduced from 70 to10 pg per 2 × 104cells and the rate of in vitro3H-thymidine incorporation increased 3–5-fold. After subcutaneous injection of tumour cells into syngeneic male hosts (Copenhagen rats), the tumour incidence was 100% (15/15) for the wild type MATLyLu cells and cells transfected with the control construct, but only 43% (9/21, P≤ 0.05) for cells transfected with TGF-β1 antisense. However, when cells were injected into immunodeficient hosts (athymic nude rats), the incidence of tumour development was 100% (10/10) for both the wild type MATLyLu cells and cells transfected with the control construct and 90% (9/10) for cells transfected with TGF-β1 antisense. These observations support the concept that MATLyLu cells are immunogenic, when the endogenous production of TGF-β1 is down-regulated. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barrack ER (1997) TGF-β in prostate cancer: A growth inhibitor that can enhance tumourigenicity. Prostate 31: 61–70
Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF and Ross R (1990) TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63: 515–524
Bender FE, Douglass LW and Dramer A (1982). Statistical methods for food and agriculture, 887–107, The AVI Publishing Co Inc: Westport, CT, USA
Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I and Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93: 2909–2914
Gomella LG, Sargent ER, Wade TP, Angland P, Lineham WM and Kasid BA (1992) Expression of transforming growth factor-α in normal human adult kidney and enhanced expression of transforming growth factor-α and -β1 in renal cell carcinoma. Cancer Res 49: 6972–6975
Isaacs JT, Yu GW and Coffey DS (1981) The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: The MATLyLu tumour. Invest Urol 9: 20–23
Isaacs JT, Isaacs WB, Feitz WF and Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261–281
Janik P, Braind P and Hartman NP (1975) The effects of estrogen-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumours. Cancer Res 35: 3698–3704
Karpus WJ and Swanborg RH (1991) CD4+ supporessor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-β. J Immunol 146: 1163–1168
Laiho M, DeCaprio JA, Ludlow JW, Livinston DM and Massague J (1990) Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175–185
Letterio JJ and Roberts AB (1998) Regulation of immune responses by TGF-β. Annu Rev Immunol 16: 137–161
Morton DM and Barrack ER (1995) Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596–2602
Pietenpol JA, Holt JT, Stein RW and Moses HL (1990) Transforming growth factor β1 suppression of c- myc gene transcription: Role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci USA 87: 3758–3762
Shaw MW, Rubenstein M, Dubin A, McKiel CF and Guinan PD (1987) Effect of cyclophosphamide on leukocytic subset distributions in rats carrying the Dunning R3327-MAT-Lylu prostatic adenocarcinoma. Prostate 11: 117–125
Sherman LA and Chattopadhyay S (1993) The molecular basis of allorecognition. Ann Rev Immunol 11: 385–402
Smolev JK, Heston WDW, Scott WW and Coffey DS (1977) Characterization of the Dunning R3327H prostatic adenocarcinoma: An appropriate animal model for prostate cancer. Cancer Treat Rep 61: 273–287
Steele RGD and Torrie JH (1960). Principles and procedures of statistics, McGraw-Hill Book Co Inc: New York
Steiner MS and Barrack ER (1992) Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vitro and in vitro. Mol Endocrinol 6: 15–25
Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B and Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumour vaccines. Cancer Res 54: 1760–1765
Welch DR, Fabra A and Nakajima M (1990) Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678–7682
Yang EY and Moses HL (1990) Transforming growth factor-β1-induced changes on cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111: 731–741
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Matthews, E., Yang, T., Janulis, L. et al. Down-regulation of TGF-β 1 production restores immunogenicity in prostate cancer cells. Br J Cancer 83, 519–525 (2000). https://doi.org/10.1054/bjoc.2000.1257
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1257
Keywords
This article is cited by
-
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Signal Transduction and Targeted Therapy (2022)
-
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Nature Medicine (2022)
-
Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression
Laboratory Investigation (2009)
-
Consequences of altered TGF-β expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects
Oncogene (2002)